Compounds > levofloxacin
Page last updated: 2024-09-04

levofloxacin and fluphenazine

levofloxacin has been researched along with fluphenazine in 5 studies

Compound Research Comparison

Studies
(levofloxacin)		Trials
(levofloxacin)		Recent Studies (post-2010)
(levofloxacin)		Studies
(fluphenazine)		Trials
(fluphenazine)		Recent Studies (post-2010) (fluphenazine)
4,3465812,2092,494400130
4,3465812,209803

Protein Interaction Comparison

ProteinTaxonomylevofloxacin (IC50)fluphenazine (IC50)
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)0.067
Potassium channel subfamily K member 2Homo sapiens (human)4.7
Tyrosine-protein kinase FynHomo sapiens (human)7.99
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)1.962
Muscarinic acetylcholine receptor M2Homo sapiens (human)7.481
Muscarinic acetylcholine receptor M4Homo sapiens (human)3.468
ATP-dependent translocase ABCB1Homo sapiens (human)6.1
Alpha-2A adrenergic receptorHomo sapiens (human)0.215
Muscarinic acetylcholine receptor M1Homo sapiens (human)2.683
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)5.7058
D(2) dopamine receptorHomo sapiens (human)0.0016
Alpha-2B adrenergic receptorHomo sapiens (human)0.029
Alpha-2C adrenergic receptorHomo sapiens (human)0.154
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)1.644
Muscarinic acetylcholine receptor M3Homo sapiens (human)4.728
D(1A) dopamine receptorHomo sapiens (human)0.023
D(4) dopamine receptorHomo sapiens (human)5.877
Sodium-dependent noradrenaline transporter Homo sapiens (human)1.962
Histamine H2 receptorHomo sapiens (human)1.226
Alpha-1D adrenergic receptorHomo sapiens (human)0.033
5-hydroxytryptamine receptor 2AHomo sapiens (human)0.0051
5-hydroxytryptamine receptor 2CHomo sapiens (human)0.067
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)1.644
Sodium-dependent serotonin transporterHomo sapiens (human)1.492
Melanocortin receptor 5Homo sapiens (human)9.518
Pleiotropic ABC efflux transporter of multiple drugsSaccharomyces cerevisiae S288C1.7
Histamine H1 receptorHomo sapiens (human)0.04
D(3) dopamine receptorHomo sapiens (human)0.0006
5-hydroxytryptamine receptor 2BHomo sapiens (human)0.039
5-hydroxytryptamine receptor 6Homo sapiens (human)0.052
Sodium-dependent dopamine transporter Homo sapiens (human)2.053
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)5.7058
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)5.7058
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.02
TPA: protein transporter TIM10Saccharomyces cerevisiae S288C31.3
ubiquitin-conjugating enzyme E2 NHomo sapiens (human)17.4345

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Andricopulo, AD; Moda, TL; Montanari, CA1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1

Reviews

1 review(s) available for levofloxacin and fluphenazine

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

4 other study(ies) available for levofloxacin and fluphenazine

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013